• Explore /
  • Poster
  • / CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Russell Kent Pachynski

Washington University School of Medicine, St. Louis, MO

Russell Kent Pachynski , Margitta Retz , Jeffrey C. Goh , Mauricio Burotto , Gwenaelle Gravis , Daniel Castellano , Aude Flechon , Stefanie Zschaebitz , David R. Shaffer , Juan Carlos Vazquez Limon , Marc-Oliver Grimm , Steven L. McCune , Neha P. Amin , Jia Li , Xuya Wang , Keziban Unsal-Kacmaz , Fred Saad , Daniel P. Petrylak , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03338790

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5044)

DOI

10.1200/JCO.2021.39.15_suppl.5044

Abstract #

5044

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Benedito A. Carneiro

First Author: Charles J. Ryan

First Author: Charles J. Ryan

First Author: Arpit Rao